Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
An Investigational Study on the Role of CYP2D6, CYP3A4 and UGTs Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy VolunteersAndrea Rodríguez-Lopez, Dolores Ochoa, Paula Soria-Chacartegui, et al.
Pharmaceutics|August 29, 2024
Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of MirabegronPaula Soria-Chacartegui, Patricia Cendoya-Ramiro, Eva González-Iglesias, et al.
Clinical Pharmacokinetics|September 17, 2020
Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic ModelingPablo Zubiaur, Lisa A Kneller, Dolores Ochoa, et al.
Human Psychopharmacology|September 29, 2020
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trialDora Koller, Susana Almenara, Gina Mejía, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 31, 2021
ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokineticsPablo Zubiaur, Miriam Del Peso-Casado, Dolores Ochoa, et al.
Journal of Immunology Research|November 28, 2015
Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque PsoriasisRocío Prieto-Pérez, Guillermo Solano-López, Teresa Cabaleiro, et al.
Frontiers in Pharmacology|May 20, 2024
Genetic variation in UGT1A1 is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trialsEva González-Iglesias, Dolores Ochoa, Manuel Román, et al.
Pharmacogenomics|September 30, 2015
The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasisRocío Prieto-Pérez, Guillermo Solano-López, Teresa Cabaleiro, et al.
Frontiers in Pharmacology|February 23, 2023
Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxineSofía Calleja, Pablo Zubiaur, Dolores Ochoa, et al.
Biomedicines|April 26, 2020
Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A SubstratesMiriam Saiz-Rodríguez, Susana Almenara, Marcos Navares-Gómez, et al.
Pageof 12